1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Oncology Center of Excellence Grows Leadership Structure, With A Vacancy Remaining

 
• By Derrick Gingery

A deputy center director position remains open and four new associate director positions were added over the last year.

US FDA's Oncology Center of Excellence celebrated its Third Anniversary on 5 February 2020.
The US FDA Oncology Center of Excellence used a 5 February public workshop to celebrate its third birthday. Not pictured is a cake with balloons that read "Happy 3rd Birthday." • Source: Derrick Gingery

In less than a year, the US Food and Drug Administration’s Oncology Center of Excellence has undergone a significant leadership shake-up with several additions and subtractions from the ranks.

Between March 2019 and January 2020, five existing positions changed hands and another was not filled following a departure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

More from Agency Leadership